Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Set Alert for Brexit

‘Keep Planning For No-Deal Brexit,’ UK Govt Tells Pharma As Chaos Grows

Amid the growing mayhem in parliament over the Brexit process, life science companies have been advised to continue preparing for the possibility that the UK might leave the EU without a deal at the end of next week. 
United Kingdom Brexit Trade

UK Drug Pricing & IP Targeted As US Gears Up For Post-Brexit Trade Deal Talks

The US has published its final negotiating objectives for a post-Brexit trade deal with the UK, which include pushing for stronger IP protections and changes to UK processes for patient access to new drugs.

United Kingdom United States Brexit

Latest From Brexit

Longer Medicine Supply Delays Expected In No-Deal Brexit

Delays in the delivery of medicines with short lead times will be longer than originally expected in the event of a no-deal Brexit, UK health care providers have been warned.

United Kingdom Brexit

Brexit And UK Procurement: Be Ready For Day 1

There are six weeks or less for medtech companies to be ready to operate as well as they can under Brexit – assuming that it will take place at the third time of asking. The new NHS procurement scheme, already in place, is another potentially disruptive concept for UK companies to adapt to.

Brexit United Kingdom

Industry Still Awaiting Clarity On Brexit Supply Chain Arrangements

As the Brexit clock continues to tick, industry says it is not impressed by government reassurances that all is well where the continued supply of medicines is concerned.

Brexit Trade

Firms Still In Dark Over No-Deal Brexit Supply Routes

Life science companies need more information on plans for alternative medicine supply routes if the UK leaves the EU without a deal, according to the BioIndustry Association, which says the release of the Operation Yellowhammer document shows the “significant impact” such an outcome would have on the sector.

Brexit United Kingdom

UK’s Own Medtech Regs: Political Turmoil Could Make November Deadline Redundant

If you are finding it difficult to follow what is happening on the broad political level in the UK as well as on the technical medtech level, you are not alone. Here we explain why Brexit-related dates are up in the air for the UK.

Regulation Brexit

Amid Brexit Chaos, UK Defers Life Sciences Spending Commitments

Sector wants R&D tax credits updated, investment in Biomedical Catalyst, and is dismayed by spending delay. 

United Kingdom Brexit

EU Urges Regulatory Compliance As UK Flounders In Brexit Chaos

The European Commission says more needs to be done to ensure that all authorized medicines are in compliance with the regulations ahead of Brexit. Meanwhile, machinations in the UK parliament have cast doubt over whether the UK will actually leave the EU at the end of October.
Europe United Kingdom

UK’s Own Device Laws Could Be Rushed Through Amidst Political Storm And Instability

The UK government has set 1 November 2019 as the date the UK’s own medtech regulations will apply, the day after the country is, in theory, due to leave the EU and potentially without a deal. But nothing is certain on the UK political scene any longer, not even this.

Medical Device Europe

UK No-Deal Medicines Regulation Under Threat As Brexit Chaos Grows

Draft regulations on medicines and medical devices could get caught up in the chaos that seems about to engulf the UK parliament as opposition MPs attempt to avert a no-deal Brexit.

United Kingdom Brexit
See All